Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339486 | 0.86 | MAPT (0.48) | KMT2AMAPTLMNANOD2NOD1 | |
| SCHEMBL6341415 | 0.80 | MEN1 (0.44) | KMT2AMEN1MAPTLMNAMAPK1 | |
| SCHEMBL7708926 | 0.78 | TSHR (0.41) | KMT2AMEN1MAPTLMNAMAPK1 | |
| SCHEMBL1495972 | 0.78 | KMT2A (0.47) | KMT2AMEN1MAPTLMNAMAPK1 | |
| SCHEMBL10474823 | 0.77 | NPC1 (0.45) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL7708940 | 0.76 | MEN1 (0.43) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL31259600 | 0.75 | CYP2C9 (0.48) | KMT2AMEN1MAPTTSHRGAA | |
| SCHEMBL7708947 | 0.75 | MEN1 (0.43) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL4539414 | 0.75 | KMT2A (0.51) | KMT2AMAPTLMNANOD2NOD1 | |
| SCHEMBL19150712 | 0.74 | ALDH1A1 (0.47) | KMT2AMEN1MAPTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940008-B1 | NOVEL BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9586905-B2 | Benzoazepine derivative and medical use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-2940008-A1 | NOVEL BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20150291533-A1 | NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-6369110-B1 | PROPHYLACTIC AGENT FOR DISEASES CAUSED BY THE ACCELERATION OF THE SODIUM/PROTON EXCHANGE TRANSPORT SYSTEM | SUMITOMO PHARMACEUTICALS COMPANY (JP) | 2002-04-09 | — | — | US | disclosed |
| EP-1083166-A1 | NOVEL SUBSTITUTED GUANIDINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291533-A1 | NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF | AVPR2, AVPR1A, AVPR1B | KMT2A 993/4885MEN1 1848/4885MAPT 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.